LY3022855 Antibodies

Target Information

LY3022855 is a biosimilar human monoclonal antibody targeting the immune checkpoint ligand PD-L1 (Programmed Death-Ligand 1) which is crucial in the evasion of immune surveillance by cancer cells. Developed by Eli Lilly this biosimilar functions as an immune checkpoint inhibitor blocking the interaction between PD-L1 on tumor cells and PD-1 receptors on T cells thus enhancing immune-mediated tumor destruction. LY3022855 is an IgG1 antibody that has been formulated to increase specificity and improve immune system activation against cancer cells. Studies involving LY3022855 focus on its efficacy as a monotherapy or in combination with other treatments in clinical settings aiming to enhance anti-tumor responses. This biosimilar is involved in research exploring the potential for extended treatment responses in various oncological applications contributing to the advancement of therapies targeting immune checkpoints.

Synonyms

Anti-PD-L1; Immune CP inhibitor